Background: Cryptosporidium parvum causes an opportunistic infection in AIDS patients, and no effective treatments are yet available. This parasite possesses a single fatty acyl-CoA binding protein (CpACBP1) that is localized to the unique parasitophorous vacuole membrane (PVM). The major goal of this study was to identify inhibitors from known drugs against CpACBP1 as potential new anti-Cryptosporidium agents.
Introduction
Cryptosporidium is well known to be a troublesome waterborne pathogen for immunocompetent and especially immunosuppressed individuals. A countless number of outbreaks, mostly caused by either Cryptosporidium parvum or Cryptosporidium hominis, occur each year around the world. Transmission is typically via contaminated water supplies and/or recreational water by the environmentally resistant and chlorine-resistant oocysts. The vulnerability of community water supplies to this parasite and increased biodefence concerns have escalated Cryptosporidium to one of the waterborne category B pathogens in the NIH and CDC biodefence research programmes.
Despite numerous investigations, there is currently no completely effective drug to treat cryptosporidiosis. Drug therapy would no doubt benefit several groups. 1 Severe cases, often requiring hospitalization among immunocompetent individuals, usually occur in children and the elderly. Transplant recipients and those undergoing cancer chemotherapy are often immunocompromised. These patients usually have to temporarily halt their treatment regimens in order to combat cryptosporidiosis. Anti-cryptosporidials would certainly be beneficial to these patients, as well as to those who are HIV-positive and are at great risk of a devastating infection with Cryptosporidium.
Several suggestions have been postulated as to why this apicomplexan appears to have a natural resistance to drug therapy. 1 One such factor is the apparent lack of or difference in drug targets at both molecular and structural levels, namely differences in biochemical pathways. Additionally, if drugs actually reach the parasite, they may be readily transported out via transport proteins. Perhaps the most widely discussed factor is the parasite's unique intracellular but extracytoplasmic location in humans and animals. [1] [2] [3] Upon initiation of infection, the infective sporozoite is enveloped by the host cell apical membrane, forming a space between the parasite and the host cell membrane known as the parasitophorous vacuole (PV). Because parasite basal membranes fuse with the host cell membrane, the PV extends only over the apical end and its membrane covering is termed the parasitophorous vacuolar membrane (PVM). Although it is unclear at this time, preliminary data indicate that the basal membranes modulate the transport of some drugs and do not allow at least some drugs to enter the parasite from host cytoplasm. 1, 4 This appears to be the case for both geneticin and the clinically relevant drug paromomycin, as apical but not basolateral exposure of these drugs led to parasite inhibition. 4 We hypothesize that parasite proteins located in the PVM may serve as valuable drug targets. One such protein is the C. parvum acyl-CoA binding protein (CpACBP1). Our laboratory has previously characterized this unique protein at both the molecular and the biochemical level. 5 This family of proteins is critical to lipid metabolism as their main function is as an intracellular acyl-CoA transporter and pool former. [6] [7] [8] Animals, plants, protists and several pathogenic bacteria have been found to contain this highly conserved protein. 9 Although they are typically small ( 10 kDa) cytosolic molecules, there have been larger (≥55 kDa) ACBPs found in animals and plants. The unique CpACBP1 is a long-type ACBP containing an N-terminal ACBP domain and a C-terminal ankyrin repeat sequence. Although it differs from the typical cytosolic ACBPs, it is similar to the membrane-bound ACBPs from Arabidopsis.
10,11 Our previous analysis indicates that CpACBP1 is also a membrane protein associated with the PVM, probably via interaction of its ankyrin repeats with other proteins in the PVM. It is unlikely that CpACBP1 is involved in the early stages of PVM formation as it is not expressed during initial stages of infection, but it is widely known that C. parvum must import fatty acids from the host cell or the intestinal lumen. Although C. parvum is incapable of de novo fatty acid synthesis, it is capable of elongating and utilizing long-chain fatty acids. [12] [13] [14] Thus, in cooperation with an acyl-CoA synthetase, it is possible that CpACBP1 serves as a fatty acyl-CoA scavenger to facilitate fatty acid uptake at the PVM.
Here we report the development of a fluorescence-based binding assay that was more sensitive and stable, and also much safer for operators, than the traditional Lipidex radioactive assay. Using the newly developed assay, we were able to produce a set of data with much improved quality regarding enzyme kinetics and substrate preference for CpACBP1. Additionally, the assay was conveniently employed to screen a library of 1040 compounds, most of which are drugs approved for use in humans for various diseases and/or ailments, to identify novel inhibitors. Several inhibitors not only inhibited the binding of CpACBP1 to fatty acyl-CoA, but also significantly reduced C. parvum growth and development in vitro, supporting the notion that CpACBP1 could potentially serve as a novel drug target in the parasite.
Materials and methods

Expression of recombinant CpACBP1 protein
We have previously cloned and expressed CpACBP1 as maltose-binding protein (MBP) fusion proteins. 5 Two forms of CpACBP1 proteins were expressed and purified in this study: the long form, containing the fulllength protein including the N-terminal ACBP domain and the C-terminal ankyrin repeats domain (CpACBP1, 268 amino acids), and the short form, containing only the ACBP domain (CpACBP1DAnk, 107 amino acids).
5
Both forms of protein were expressed in a Rosetta 2 strain of Escherichia coli cells (Novagen) and purified using amylose resin-based affinity chromatography according to the manufacturer's standard protocol (New England Biolabs) as described.
5 Purified proteins were dialysed extensively against Dulbecco's PBS (Sigma) and stored at 2808C.
Development of fluorometric assay for CpACBP1
A fluorescence-based assay was developed to replace the conventional radioactive assay. This was achieved by taking advantage of the unusual feature of nitrobenzoxadiazole (NBD)-that it is nearly non-fluorescent in aqueous solution, but can produce increased fluorescence in a polar environment such as in the binding pocket of an enzyme. 15 In this assay, the emission of NBD-labelled palmitoyl-CoA (NBD-C16:0-CoA) upon binding to CpACBP1 was measured in a Fluoroskan Ascent fluorimeter using a pair of bandpass filters at 538+12.5 nm for emission and 460+9.0 nm for excitation (Thermoelectron). All reactions were set up in 96-well white plates, which offer high signal reflectance and reduced background fluorescence (Thermoelectron). The fluorimeter program was set to maintain a constant temperature of 258C and to shake the samples for 20 s at 120 rpm (1 mm diameter rotation) prior to fluorescence measurement. An average of three to five scans was taken for each measurement, with at least three replicates for each experiment.
Enzyme kinetics and substrate preference
We also determined the major binding kinetics and substrate preference for CpACBP1 using the NBD-C16-CoA-based assay to compare with those previously reported by us using a Lipidex 1000 assay. First, the pH of the reaction was optimized using PBS at pH 5.5, 6.0, 6.5, 7.0, 7.5, 8.0 and 8.5. In addition to PBS, reaction components consisted of 0.1 mM MBP-CpACBP1 and 0.25 mM NBD-C16:0-CoA in a volume of 100 mL. Enzyme kinetics assays were performed using 0.1 mM MBP-CpACBP1, NBD-C16:0-CoA (16 nM-1 mM) and PBS, pH 7.5, to a final volume of 100 mL. We also employed a substrate competition assay to determine substrate specificity using this assay set-up. Assays included 0.1 mM MBP-CpACBP1, 0.25 mM NBD-C16:0-CoA, 0.25 mM unlabelled saturated (C2:0-C26:0) or unsaturated (C18:1, C18:3, C20:4 and C22:6) fatty acylCoAs and PBS, pH 7.5, in a final volume of 100 mL. In addition we also assayed the binding of palmitic acid (C16:0) to CpACBP1. For each assay, the enzyme was the final reaction component added and reactions were incubated at 258C for 5 min to ensure maximum binding before proceeding with fluorescence measurements.
Screening of compound library against CpACBP1
We were graciously given access to a drug library consisting of 1040 compounds by Dr Friedhelm Schroeder (Texas A&M University). 16 This library was purchased from Microsource Discovery Systems as the NIH and Juvenile Diabetes Research Foundation (NIH/JDRF) custom collection. Each compound was provided dissolved in DMSO at a concentration of 10 mM, and was diluted to 10 mM in PBS, pH 7.5, prior to the assay. Thus, the final concentration of DMSO in the assay was 0.0025%.
Fritzler and Zhu
Our primary screening was carried out using a single concentration of compound. A typical reaction contained 0.1 mM MBP-CpACBP1, 0.25 mM NBD-C16:0-CoA and 0.25 mM library compound in a final volume of 100 mL of PBS (pH 7.5). MBP was used in control reactions for background subtraction. Assays were performed in duplicate. Reactions were started by adding enzyme or MBP as the final component, and fluorescence emission at 538 nm was measured after the reactions had been incubated at 258C for 5 min.
After primary screening, the absorption spectra of compounds that displayed ≥50% inhibition on the binding of NBD-C16:0-CoA to MBP-CpACBP1 were tested. Compounds that displayed absorption spectra at 280-590 nm were excluded from subsequent kinetic analysis. Detailed inhibitory kinetic features were determined for the remaining effective compounds using a series of concentrations ranging from 20 nM to 2 mM. The IC 50 values were derived from the data by appropriate non-linear regression algorithms depending on the observed curves (typically sigmoidal or hypobolic curves). The K i values were derived from the following formula:
where S is the concentration of NBD-C16:0-CoA (0.25 mM).
Cultivation of parasite in vitro for drug testing
Only C. parvum oocysts (Iowa strain) ,3 months old since the time of harvest were used in all experiments. Oocysts were purified by Percoll gradient centrifugation and bleached as previously described. 17, 18 Human ileocaecal colorectal adenocarcinoma (HCT-8) cells (1×10 5 / well) were seeded in 48-well tissue culture plates and allowed to grow overnight or until they reached 80% confluency at 378C with 5% CO 2 in RPMI 1640 medium (Sigma) containing 10% fetal bovine serum and other supplements as described previously. 19, 20 For drug testing, host cells were infected with 20000 oocysts per well. In all experiments, parasites were allowed to incubate for 3-4 h at 378C for excystation and invasion into host cells. Parasites that failed to invade host cells were removed by replacing the culture medium with one that contained specified concentrations of compounds. The treated parasite-infected cells were then incubated at 378C with 5% CO 2 for 44 h. An initial screening using high (1 mM) and low (10 mM) concentrations of compounds was first performed in order to determine the range of effective concentrations in kinetics assays. Only those that could inhibit parasite growth in the initial test were further tested for their inhibitory kinetics at concentrations ranging from 0 to 1.0 mM. Negative controls, which received no parasites and/or no treatment, were included in each experiment. Positive controls used paromomycin, the commonly used laboratory standard for in vitro drug testing. At least two wells in different plates were employed for each experimental condition, and all experiments were repeated at least in triplicate.
Quantitative analysis of drug efficacy regarding parasite growth using quantitative RT-PCR Total RNA was isolated from parasite-infected cells at 44 h post-infection using the RNeasy isolation kit (Qiagen). The concentration and quality of the RNA in each sample were determined by measuring absorbances at 260 and 280 nm. All RNA samples were adjusted to a concentration of 20 ng/mL for use in quantitative RT-PCR (qRT-PCR). A SYBR Green-based real time qRT-PCR method was used to detect parasite 18S rRNA using a pair of previously published primers: 995F (5 ′ TAG AGA TTG GAG GTT GTT CCT 3 ′ ) and 1206R (5 ′ CTC CAC CAA CTA AGA ACG GCC 3 ′ ). 12, 19, 21 For normalization, human 18S rRNA levels were also detected for each sample using the previously published primer pair F1373 (5 ′ CCG ATA ACG AAC GAG ACT CTG G 3 ′ ) and R1561 (5 ′ TAG GGT AGG CAC ACG CTG AGC C 3 ′ ). 12, 22 Reaction mixtures containing 20 ng total RNA and appropriate amounts of reagents and primers were first incubated at 488C for 30 min to synthesize cDNA, heated at 958C for 15 min to inactivate the reverse transcriptase, and then subjected to 40 thermal cycles (958C for 20 s, 508C for 30 s and 728C for 30 s) of PCR amplification with an iCycler iQ real-time PCR detection system (Bio-Rad Laboratories). At least two reaction replicates were performed for each experimental condition, and each experiment was performed in at least triplicate.
Quantitative analysis was carried out as previously described by our laboratory. 22 Inhibition curves derived from quantitative analysis were subjected to non-linear regression against log-transformed compound concentrations using the Prism v4.03 program (GraphPad Software). The IC 50 for each compound was derived from the sigmoidal model by determining the compound concentrations that resulted in a 50% reduction of parasite growth when compared with the growth of the controls.
In vitro cytotoxicity assay
To ensure that apparent parasite inhibition was not in fact due to the compounds actually inhibiting the host cells, we analysed host cell inhibition using an MTT-based in vitro Toxicology Assay Kit (Sigma). All Novel anti-Cryptosporidium activity of known drugs 611 JAC four compounds were tested at both high (1 mM) and low (10 mM) concentrations. Positive controls included paromomycin at 0.8 mg/mL and 0.1 mg/mL. Negative controls that included no compound were included in each experiment as a baseline. At least two wells in different plates were employed for each experimental condition, and all experiments were repeated in at least triplicate.
Results
Determination of CpACBP1 binding activity and substrate preference
We observed increased fluorescence emission at 538 nm by NBD-C16:0-CoA upon binding to CpACBP1 protein (Figure 1a) . The binding was specific, as the MBP-tag control group emitted virtually no signal. The binding was affected by pH, and the optimal condition for binding was determined to be pH 7.5 (Figure 1b) . Using this fluorometric assay, we determined that CpACBP1 had a dissociation constant (K d ) of 171.2 nM towards NBD-C16:0-CoA (Figure 2 ). We also assayed the short form CpACBP1 without the ankyrin repeats domain (CpACBP1DAnk) and observed a slight reduction in its binding affinity towards NBD-C16:0-CoA (i.e. K d ¼ 366.7 nM) (Figure 2 ), which suggests that the ankyrin repeats might also contribute to the conformational stability of the protein in addition to their usual involvement in interacting with other proteins or molecules. When various unlabelled fatty acyl-CoA esters were included in the reactions to compete with NBD-C16:0-CoA at an equal molar concentration of 25 mM, CpACBP1 displayed preferential binding towards short-to long-chain fatty acyl CoA esters (i.e. C4:0 to C16:0) (Figure 3 ). CpACBP1 had decreased binding affinities towards very long chain esters (C18:0 to C24:0) and little or no binding affinity towards the four unsaturated fatty acyl 
Presence of CpACBP1 inhibitors in the compound library and their inhibition kinetics
Primary screening of the NIH/JDRF compound library using the fluorometric assay identified 37 (3.56%) out of the 1040 compounds that displayed ≥50% inhibition of binding between CpACBP1 and NBD-C16:0-CoA. Among them, nine displayed absorption spectra in the 580-600 nm range, which could interfere with the assay, and were thus excluded from subsequent analysis. The remaining 28 (2.7%) top compounds were further tested, and their IC 50 values were determined to range between 0.018 mM (acetazolamide) and 0.811 mM (homatropine methylbromide) ( Table 1 ). As shown in Table 1 , these top compounds possess a diverse range of bioactivities, ranging from antiviral, antibacterial, antifungal and antiparasitic to anti-inflammatory and antidepressant. The observed anti-ACBP activity was novel for these drugs.
Inhibition of parasite growth in vitro by CpACBP1 inhibitors
The top 28 compounds shown to inhibit the binding of NBD-C16:0-CoA to CpACBP1 were further tested for their effect on C. parvum growth in vitro. Our initial in vitro drug testing with two concentrations of drugs (10 mM and 1 mM) first identified four compounds that were effective against parasite growth in vitro. None of the other 24 compounds displayed any inhibition at either low or high concentration. More detailed drug testing revealed that the four compounds could inhibit parasite growth in vitro with low micromolar IC 50 values. These effective compounds included broxyquinoline (IC 50 64.9 mM), cloxyquin (IC 50 25.1 mM) and cloxacillin sodium (IC 50 36.2 mM), which are known antibacterial or antifungal agents, as well as sodium dehydrocholate (IC 50 53.2 mM), which is a semi-synthetic bile salt and a choleretic agent (Figure 4 ). These IC 50 values for parasite growth in vitro were 250-500 times higher than those for CpACBP1 binding to fatty acyl-CoA. Additionally, these four compounds displayed little or no toxicity towards host HCT-8 cells at IC 50 concentrations, although low levels of cytotoxicity were observed at much higher concentrations (10 mM to 1 mM) Compounds that were used to test their antiparasitic protozoal activities by other investigators (see Table 2 for more detail). c Compounds that displayed anti-cryptosporidial activities in this study (see Figure 4 for more detailed kinetics).
Novel anti-Cryptosporidium activity of known drugs 613 JAC ( Figure 5 ). As a positive control, paromomycin displayed expected efficacy with an IC 50 value of 112.3 mM, which is close to values reported previously. 22 
Discussion
The binding kinetics between ACBP and fatty acyl-CoA have traditionally been determined with a Lipidex 1000 assay. 5, 23, 24 Because this conventional assay uses radioactive materials, it is less safe and unfriendly for high-throughput screening (HTS).
Lipidex resin also competes with ACBP when used to remove unbound substrates, which compromises the assay's sensitivity and accuracy. In contrast, the newly developed NBD-based fluorometric assay overcomes these weaknesses, particularly when used for HTS of CpACBP1 inhibitors. The fluorescence emission of NBD is highly environmentally sensitive. This feature has been explored to study various fatty acid and fatty acyl-CoA binding proteins from other organisms using NBD-labelled fatty acids or stearic CoA. 6, 15, 25 A more recent example is the use of NBD-C16:0-CoA to study in vitro acyl CoA:diacylglycerol Fritzler and Zhu acyltransferase activity. 26 In the present study, we developed a fluorescence assay using NBD-C16:0-CoA to study the binding properties and HTS of inhibitors of CpACBP1, which to our knowledge is the first such study of an ACBP family protein.
The new fluorescence assay produced a K m value of 171.2 nM for the binding of full-length CpACBP1 to radioactive C16:0-CoA, which is 2.4-fold lower than, but comparable to, the value obtained in our previous study using the Lipidex 1000 assay (i.e. 405 nM). 5 The newly obtained substrate preference data were also similar to those obtained previously, except that CpACBP1 was unable to bind acyl-CoA esters with ≥20 carbons using the Lipidex 1000 assay.
5 These slight differences in both K m values and substrate preferences are likely due to the binding competition between ACBP and Lipidex 1000 resin during the extraction step of the assay. 5, 27 It is also possible that the presence of the NBD group in the fatty acyl-CoA might slightly change the binding affinity.
Using the fluorescence assay, we also performed HTS of 1040 compounds and identified 28 top candidates that could inhibit CpACBP1 binding activity by ≥50% at 0.25 mM. Subsequent in vitro drug testing identified 4 of the 28 compounds that displayed efficacy against parasite growth in vitro at low micromolar levels. These included b-lactamase-resistant penicillin (cloxacillin sodium) and two quinoline derivatives (broxyquinoline and cloxyquin), which are known for their antibacterial, antifungal and antiprotozoal activities, [28] [29] [30] as well as a semisynthetic bile salt (sodium dehydrocholate), which is primarily used as a choleretic agent. 31, 32 These data are the first to show that these four drugs could target an ACBP protein and inhibit the growth of an apicomplexan parasite in vitro. Their in vitro IC 50 values range from around 25 to 65 mM, which are about 4-to 65-fold higher than the values for the FDA-approved anti-cryptosporidial drug nitazoxanide (IC 50 1-4 mM), but about 1.7-4.5× lower than that of paromomycin (IC 50 112.3) as determined in this study or reported previously (IC 50 125-170 mM).
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It is noticeable that acetazolamide and tyrothricin were the two most effective compounds in inhibiting CpACBP1 binding activity (IC 50 0.018 and 0.039 mM, respectively) ( Table 1) . However, these two compounds displayed no efficacy against parasite growth in vitro, which ruled out their potential as anti-cryptosporidial drugs. On the other hand, their extremely high affinity to CpACBP1 indicates that their analogues are worth examining.
We studied at least 8 out of the top 28 compounds in greater detail for their effects on several other parasitic protozoa (Table 2 ). Only three of the drugs presented here have previously been tested as treatments for cryptosporidiosis. Among them, bithionol was shown to be relatively inactive in in vitro studies. 33 In another study, rifampicin reduced the number of parasites by only 17.4% when used at a concentration of 8 mg/mL and by 74.4% when used in combination with 50 mM ranalexin. 34 These observations are congruent with our in vitro drug testing data on the ineffectiveness of bithionol and rifampicin on C. parvum growth. On the other hand, in two uncontrolled studies with a small number of patients with HIV infection, treatments with rifaximin resulted in resolution of clinical symptoms and the clearance of infection. 35 In the present study, rifaximin could effectively inhibit CpACBP1 binding activity (IC 50 0.227 mM) (Table 1) . However, it displayed no effect on parasite growth in our primary in vitro drug testing at both 10 mM and 1.0 mM. If rifaximin is truly effective in treating cryptosporidial infection in patients, our data imply that CpACBP1 could be its target, or at least one of its targets, whereas the ineffectiveness of rifaximin under in vitro conditions might be explained as follows. First, rifaximin may have different absorption kinetics between in vitro and in vivo conditions. Second, this drug may be more effective on the later sexual development and/or Novel anti-Cryptosporidium activity of known drugs 615 JAC oocyst formation stages of C. parvum, which could not be detected by the current 2 day in vitro drug assay. ACBP has been characterized as a family of housekeeping proteins that plays a critical and regulatory role in lipid metabolism. 27 These proteins bind and sequester fatty acyl-CoA esters and act as an intracellular acyl-CoA transporter and pool former. The parasite C. parvum possesses only a single ACBP (CpACBP1). It is localized to the unique host cell membranederived PVM, which separates the extracytoplasmic parasite from the extracellular environment, such as the gut. The present study not only identified a number of known drugs that could serve as CpACBP1 inhibitors, but also indicated that several of them could in fact inhibit the growth of C. parvum in vitro by targeting CpACBP1, probably by making the parasite incapable of further processing fatty acids. These observations suggest that CpACBP1 and PVM may serve as novel drug targets in the treatment of cryptosporidial infection.
Because these effective compounds are known drugs, it is worth further testing their potential effects against cryptosporidial infection in vivo. If satisfactory efficacies could be observed, these drugs might be quickly repurposed to treat cryptosporidiosis, for which effective treatments are currently unavailable for immunocompromised patients. Additionally, the four top drugs may also serve as leads for synthesizing new analogues in future studies to identify more effective anti-cryptosporidial drugs.
